Results 231 to 240 of about 492,046 (298)

Nail Disorders in Systemic Conditions

JEADV Clinical Practice, EarlyView.
ABSTRACT Nail findings in children can be indicative of an underlying systemic disease. Many of these findings are seen in multiple entities and are not specific to one disease. The importance of specifically examining for these nail changes cannot be overstated.
Jane Sanders Bellet
wiley   +1 more source

Neurodevelopmental origins of structural and psychomotor defects in CXCR4-linked primary immunodeficiency.

Neuron
Demenego G, Mancinelli S, Borreca A, Proce RO, Aragona V, Miotto M, Cremonesi M, Zucchelli L, Corradini I, Kim E, Ilic K, Fraviga E, Pellegrino L, Badolato R, Rusconi R, Pozzi D, Kallikourdis M, Cash D, Matteoli M, Lodato S.   +19 more
europepmc   +1 more source

Recommendations for Transitioning Young People with Primary Immunodeficiency Disorders and Autoinflammatory Diseases to Adult Care. [PDF]

J Clin Immunol
Israni M, Alderson E, Mahlaoui N, Obici L, Rossi-Semerano L, Lachmann H, Avramovič MZ, Guffroy A, Dalm V, Rimmer R, Solis L, Villar C, Gennery AR, Skeffington S, Nordin J, Warnatz K, Korganow AS, Antón J, Cattalini M, Berg S, Soler-Palacin P, Campbell M, Burns SO, ESID Clinical Working Party, ERN RITA Transition Working Group Consortium.   +24 more
europepmc   +1 more source

RTA‐408 Enhances Radiosensitivity and Inhibited Tumor Progression via JNK Pathway in Glioblastoma

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis owing to its high invasiveness and resistance to therapy. RTA‐408, a synthetic triterpenoid and nuclear factor erythroid 2‐related factor 2 activator, exhibits anti‐inflammatory and anti‐cancer properties; however, its effects on GBM remain unclear. This study investigated the
Hung‐Pei Tsai, Hao Qin, Yoon Bin Chong, I‐Hsiang Chen, Shih‐Hsun Kuo, Tzu‐Ting Tseng, Ann‐Shung Lieu   +6 more
wiley   +1 more source

Immunoglobulin therapies for primary immunodeficiency diseases (part 1): understanding the pharmacokinetics. [PDF]

Immunotherapy
Mahmood I, Li Z.
europepmc   +1 more source

PRIMARY IMMUNODEFICIENCY [PDF]

, 1991
openaire   +1 more source

A Multicentric Clinical Study to Evaluate Pharmacokinetics, Efficacy, and Safety of Immune Globulin Subcutaneous 20% Weekly/Biweekly Dosing in Treatment-Experienced Patients and Loading/Weekly Maintenance Dosing in Treatment-Naïve Patients with Primary Immunodeficiency. [PDF]

J Clin Immunol
Lumry WR, Palumbo M, Hsu C, Hussain I, McNeil D, Bridges T, Wedner HJ, Scarupa M, Mondou E, Nanaware-Kharade N, Hanna K, Coll MQ, Oliveras J.   +12 more
europepmc   +1 more source

Primary Immunodeficiency-Type Ataxia-Telangiectasia Revealed by Splenic Abscesses. [PDF]

Cureus
Bebana A, Ghanam A, Tkak H, Elouali A, Babakhouya A, Rkain M.   +5 more
europepmc   +1 more source

Lymphoproliferation, Autoimmunity, and Recurrent Infections: Which Primary Immunodeficiency? [PDF]

Turk Arch Pediatr
Öztürk G, Haskoloğlu Ş, Deveci N, Erkmen H, Çelik NA, Sucak G, Ceylaner S, İkincioğulları A, Doğu F.   +8 more
europepmc   +1 more source

Albinism and Primary Immunodeficiency in Infants: A Case Study of Griscelli Syndrome. [PDF]

Cureus
Bouhafs N, N'joumi C, Elouali A, Babakhouya A, Rkain M, Benajiba N.   +5 more
europepmc   +1 more source